12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Clivatuzumab-based blood test diagnostic data

Data from >600 blood samples from patients with various forms of pancreatic cancer, cancers of the surrounding organs, benign pancreatic disease and healthy volunteers showed that Immunomedics' clivatuzumab-based blood test had 76% sensitivity for detecting pancreatic ductal adenocarcinoma. When combined with the CA19-9 tumor marker, the sensitivity...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >